Clinical Trial Results of the HER-2/neu (E75) Vaccine to Prevent Breast Cancer Recurrence in High-Risk Patients: From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

BACKGROUND: The authors conducted exploratory phase 1–2 clinical trials vaccinating breast cancer patients with E75, a human leukocyte antigen (HLA) A2/A3–restricted HER-2/neu (HER2) peptide, and granulocyte-macrophage colony-stimulating factor. The vaccine is given as adjuvant therapy to prevent di...

Full description

Saved in:
Bibliographic Details
Main Authors: Mittendorf, Elizabeth A., Clifton, Guy T., Holmes, Jarrod P., Clive, Kevin S., Patil, Ritesh, Benavides, Linda C., Gates, Jeremy D., Sears, Alan K., Stojadinovic, Alexander, Ponniah, Sathibalan, Peoples, George E.
Format: Artigo
Language:Inglês
Published: 2011
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3428069/
https://ncbi.nlm.nih.gov/pubmed/21989902
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.26574
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items